ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Bosutinib is an orally active dual Src/Abl TKI that was approved in 2012 in the United States for the treatment of patients with Ph+ CML resistant to or intolerant of prior therapy (Pfizer Labs, 2015).